Bogdan Balas

4.7k total citations · 1 hit paper
36 papers, 3.6k citations indexed

About

Bogdan Balas is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Bogdan Balas has authored 36 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 11 papers in Pulmonary and Respiratory Medicine and 11 papers in Oncology. Recurrent topics in Bogdan Balas's work include Lung Cancer Research Studies (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Metabolism, Diabetes, and Cancer (8 papers). Bogdan Balas is often cited by papers focused on Lung Cancer Research Studies (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Metabolism, Diabetes, and Cancer (8 papers). Bogdan Balas collaborates with scholars based in United States, Switzerland and Italy. Bogdan Balas's co-authors include Ralph A. DeFronzo, Kenneth Cusi, Amalia Gastaldelli, Stephen A. Harrison, Steven Schenker, Masafumi Matsuda, Muhammad Abdul-Ghani, Celia Darland, Ralph A. DeFronzo and Jean Hardies and has published in prestigious journals such as New England Journal of Medicine, Molecular and Cellular Biology and Hepatology.

In The Last Decade

Bogdan Balas

35 papers receiving 3.5k citations

Hit Papers

A Placebo-Controlled Trial of Pioglitazone in Subjects wi... 2006 2026 2012 2019 2006 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
    2006 1.4k citations Renata Belfort, Stephen A. Harrison et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bogdan Balas United States 18 1.8k 1.6k 1.1k 700 587 36 3.6k
Tadashi Namisaki Japan 29 1.5k 0.9× 539 0.3× 952 0.9× 238 0.3× 500 0.9× 159 3.3k
Silvia Frascerra Italy 28 525 0.3× 2.3k 1.4× 1.3k 1.1× 814 1.2× 1.4k 2.4× 54 3.9k
Satoru Kakizaki Japan 32 1.1k 0.6× 500 0.3× 666 0.6× 193 0.3× 771 1.3× 189 3.4k
Mark M. Smits Netherlands 29 705 0.4× 2.5k 1.6× 826 0.7× 402 0.6× 1.4k 2.3× 68 3.8k
Pi‐Jung Hsiao Taiwan 29 538 0.3× 606 0.4× 569 0.5× 377 0.5× 661 1.1× 84 2.1k
Naohiko Sakai Japan 37 1.2k 0.7× 1.8k 1.1× 1.2k 1.1× 666 1.0× 2.2k 3.8× 90 4.8k
Etsuko Hashimoto Japan 35 4.4k 2.5× 1.8k 1.1× 681 0.6× 409 0.6× 771 1.3× 107 5.2k
Lance Yi Xu New Zealand 11 2.2k 1.3× 585 0.4× 701 0.6× 920 1.3× 277 0.5× 12 2.8k
Óscar Beloqui Spain 34 754 0.4× 247 0.2× 557 0.5× 471 0.7× 438 0.7× 85 2.9k
Christos Tikellis Australia 25 402 0.2× 1.2k 0.8× 1.1k 1.0× 339 0.5× 531 0.9× 30 3.7k

Countries citing papers authored by Bogdan Balas

Since Specialization
Citations

This map shows the geographic impact of Bogdan Balas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bogdan Balas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bogdan Balas more than expected).

Fields of papers citing papers by Bogdan Balas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bogdan Balas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bogdan Balas. The network helps show where Bogdan Balas may publish in the future.

Co-authorship network of co-authors of Bogdan Balas

This figure shows the co-authorship network connecting the top 25 collaborators of Bogdan Balas. A scholar is included among the top collaborators of Bogdan Balas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bogdan Balas. Bogdan Balas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wachter, Rolf, et al.. (2019). Real-World Treatment Patterns of Sacubitril/Valsartan: A Longitudinal Cohort Study in Germany. European Journal of Heart Failure. 21(5). 588–597. 43 indexed citations
3.
Novello, Silvia, Julien Mazières, In‐Jae Oh, et al.. (2018). Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Annals of Oncology. 29(6). 1409–1416. 243 indexed citations
4.
Gadgeel, Shirish M., Solange Peters, Tony Mok, et al.. (2018). Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Annals of Oncology. 29(11). 2214–2222. 215 indexed citations
5.
Jackson, James, et al.. (2018). Care pathways and treatment patterns for patients with heart failure in China: results from a cross-sectional survey. Drug Design Development and Therapy. Volume 12. 2311–2321. 4 indexed citations
6.
Wachter, Rolf, Sven Klebs, Matthias Schindler, et al.. (2018). Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany. Postgraduate Medicine. 130(3). 308–316. 19 indexed citations
7.
Gagne, Joshua J., James R. Rogers, Chun‐Lan Chang, et al.. (2018). Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data. Journal of Comparative Effectiveness Research. 7(11). 1073–1082. 1 indexed citations
8.
Mok, Tony, Solange Peters, D. Ross Camidge, et al.. (2017). Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study. Annals of Oncology. 28. x191–x191. 8 indexed citations
9.
Gadgeel, Shirish M., Solange Peters, Tony Mok, et al.. (2017). Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study. Annals of Oncology. 28. v638–v639. 13 indexed citations
10.
Novello, Silvia, Julien Mazières, In‐Jae Oh, et al.. (2017). Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC). Annals of Oncology. 28. v639–v639. 18 indexed citations
11.
Castro, Javier de, Silvia Novello, Julien Mazières, et al.. (2017). CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC. Annals of Oncology. 28. v481–v481. 6 indexed citations
12.
Barlési, Fabrice, Anne‐Marie C. Dingemans, James Chih‐Hsin Yang, et al.. (2016). Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC). Annals of Oncology. 27. vi437–vi437. 11 indexed citations
13.
Muscogiuri, Giovanna, Amrita Kamat, Bogdan Balas, et al.. (2011). β-Adrenergic Responsive Induction of Insulin Resistance in Liver of Aging Rats. Endocrine Research. 36(2). 74–82. 7 indexed citations
14.
Liang, Huiyun, Bogdan Balas, Puntip Tantiwong, et al.. (2009). Whole body overexpression of PGC-1α has opposite effects on hepatic and muscle insulin sensitivity. American Journal of Physiology-Endocrinology and Metabolism. 296(4). E945–E954. 73 indexed citations
15.
Gastaldelli, Amalia, Stephen A. Harrison, L. Jean Hardies, et al.. (2009). Importance of Changes in Adipose Tissue Insulin Resistance to Histological Response During Thiazolidinedione Treatment of Patients with Nonalcoholic Steatohepatitis†. Hepatology. 50(4). 1087–1093. 223 indexed citations
16.
Coletta, Dawn K., Bogdan Balas, Alberto O. Chávez, et al.. (2008). Effect of acute physiological hyperinsulinemia on gene expression in human skeletal muscle in vivo. American Journal of Physiology-Endocrinology and Metabolism. 294(5). E910–E917. 70 indexed citations
17.
Abdul‐Ghani, Muhammad, Florian L. Müller, Yuhong Liu, et al.. (2008). Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance. American Journal of Physiology-Endocrinology and Metabolism. 295(3). E678–E685. 116 indexed citations
18.
Balas, Bogdan, et al.. (2007). The Role of Dipeptidyl Peptidase-4 Inhibitors in the Management of Type 2 Diabetes. touchREVIEWS in Endocrinology. 45–45.
19.
Balas, Bogdan, Renata Belfort, Stephen A. Harrison, et al.. (2007). Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. Journal of Hepatology. 47(4). 565–570. 69 indexed citations
20.
Belfort, Renata, Stephen A. Harrison, Celia Darland, et al.. (2006). A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis. New England Journal of Medicine. 355(22). 2297–2307. 1402 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tadashi Namisaki Breakdown of academic impact, for papers by Silvia Frascerra Breakdown of academic impact, for papers by Satoru Kakizaki Breakdown of academic impact, for papers by Mark M. Smits Breakdown of academic impact, for papers by Pi‐Jung Hsiao Breakdown of academic impact, for papers by Naohiko Sakai Breakdown of academic impact, for papers by Etsuko Hashimoto Breakdown of academic impact, for papers by Lance Yi Xu Breakdown of academic impact, for papers by Óscar Beloqui Breakdown of academic impact, for papers by Christos Tikellis
Rankless by CCL
2026